Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vepdegestrant plus PF-07220060 in ER-positive/HER2-negative advanced or metastatic breast cancer
jRCT2031230677Phase 2Active, not recruiting
- Sponsor
- Pfizer
- Start
- Feb 2024
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Small Molecules
01
Overview
Phase 2, open-label trial of vepdegestrant and atirmociclib in breast cancer (2 arms), sponsored by Pfizer. Primary endpoints: Number of participants with dose-limiting toxicities and Objective response rate by investigator assessment. Started Feb 2024; status: active, not recruiting.
02
Drugs
vepdegestrantatirmociclib
03
Conditions
breast cancer
Beyond the preview
Go deeper on jRCT2031230677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230677.